Recent studies support the ability of low doses of STING agonists cGAMP and ADU-S100 (also known as ML-RR-S2-CDA, MIW815) to promote the local production of anti-angiogenic factors that facilitate vascular normalization when injected intratumorally in mice bearing established breast carcinoma, lung carcinoma or melanoma [31,32]. Here, STING1 is linked to melanoma.